Sana Biotechnology (SANA) Cash from Financing Activities (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Cash from Financing Activities data on file, last reported at -$128000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 113.03% year-over-year to -$128000.0; the trailing twelve-month figure through Mar 2026 stood at $127.6 million (up 790.35% YoY), and the FY2025 full-year result was $128.7 million, down 35.55% from the prior year.
• Cash from Financing Activities retreated to -$128000.0 in Q1 2026, from $17.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $186.4 million in Q1 2024 to a low of -$128000.0 in Q1 2026.
• A 5-year average of $21.5 million and a median of $1.6 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 78881.78% in 2024 and slumped 113.03% in 2026, its largest moves.
• Tracing SANA's Cash from Financing Activities over 5 years: stood at $1.1 million in 2022, then soared by 61.92% to $1.7 million in 2023, then plunged by 62.57% to $643000.0 in 2024, then jumped by 2644.95% to $17.6 million in 2025, then slumped by 100.73% to -$128000.0 in 2026.
• Business Quant data shows SANA's Cash from Financing Activities at -$128000.0 in Q1 2026, $17.6 million in Q4 2025, and $109.5 million in Q3 2025.